Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8416 to 8430 of 8967 results

  1. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

  2. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    Discontinued Reference number: GID-TA11411

  3. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

  4. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]

    In development Reference number: GID-TA11629 Expected publication date: TBC

  5. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  6. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

  7. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

  8. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued Reference number: GID-TAG232

  9. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

  10. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

  11. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

  12. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

  13. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued Reference number: GID-TA11173

  14. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued Reference number: GID-TA10474